Diabetes care platform eyes £125,000 funding target

The developer of a diabetes care platform is eyeing a £125,000 crowdfunding target with the aim of supporting the firm’s expansion.

Spotlight Consultations’ evidence-based Spotlight-AQ aims to be a simple, three-to-five-minute questionnaire, dynamically responsive with each question linked to an actionable care pathway.

Visual graphics show results and therapy options that are shared with healthcare professionals, facilitating shared decision-making to meet individual needs.

The company aims to produce digital health tools that scale to different national and international health services, different languages and contain inbuilt audio/colour versions for people with low literacy.

Professor Katherine Barnard, Spotlight CSO, said: “The benefits of the platform are that it addresses an urgent unmet need within routine care.

“Year-on-year, national audit data shows poor health outcomes for the majority of people with diabetes. What Spotlight Consultations clinical e-tools do is help patients step away from thinking purely about biomedical outcomes and look more broadly about how diabetes impacts their everyday life and vice versa.

“By providing clarity of patient needs, it enables healthcare professionals to personalise healthcare and work collaboratively with each patient for better health and well-being.”

At the time of writing, the company has currently raised £63,335 from 55 investors on Crowdcube.

Barnard added: “The funding we raise through Crowdcube will enable us to focus on market access to get our newly built commercial platform out to clinics as soon as possible.

“At the same time, it will go towards building audio/colour and different language versions of the tools to reduce health inequality and ensure all people with diabetes, irrespective of socio-economic status, diversity or health literacy are able to use them.

“Finally, if we raise sufficient funds, it will speed up development of additional e-tools for cardiovascular disease, chronic obstructive pulmonary disorder, irritable bowel disease and chronic pain.”